Phosphorylation status of fas-associated death domain-containing protein regulates telomerase activity and strongly correlates with prostate cancer outcomes

Pathobiology

Volumn 76, Issue 6, 2009, Pages 293-302

  Matsumura, Yoshiaki ^a   Shimada, Keiji ^a   Tanaka, Nobumichi ^a   Fujimoto, Kiyohide ^a   Hirao, Yoshihiko ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

FADD phosphorylation; HTERT; Prostate cancer

Indexed keywords

FAS ASSOCIATED DEATH DOMAIN PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE;

AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; WILD TYPE;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROSTATECTOMY; PROSTATIC NEOPLASMS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 72449136774     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245895     Document Type: Article

References (29)

1. Witjes WP, Schulman CC, Debruyne FM: Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997; 49: 65-69.
2. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, Chin J, Chatterjee S: Long-term followup of a randomized trial of versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 791-794.
3. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/ APO-1- and TNF receptor-induced cell death. Cell 1996; 85: 803-815.
4. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death domaincontaining protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
5. Tibbetts MD, Zheng L, Lenardo MJ: The death effector domain protein family: regulators of cellular homeostasis. Nat Immunol 2003; 4: 404-409.
6. Scaffidi C, Volkland J, Blomberg I, Hoffmann I, Krammer PH, Peter ME: Phosphorylation of FADD/MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J Immunol 2000; 164: 1236-1242.
7. Zhang J, Cado D, Chen A, Kabra NH, Winoto A: Fas-mediated apoptosis and activationinduced T-cell proliferation are defective in mice lacking FADD/MORT1. Nature 1998; 392: 296-300.
8. Zhang J, Kabra NH, Cado D, Kang C, Winoto A: FADD-deficient T cells exhibit a disaccord in regulation of the cell cycle machinery. J Biol Chem 2001; 276: 29815-29818.
9. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Konishi N: Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. J Pathol 2005; 206: 423-432.
10. Shay JW, Wright WE: Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005; 26: 867-874.
11. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Kishi M, Konishi N: Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis. Carcinogenesis 2004; 25: 1089-1097.
12. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, Lopez-Otin C, Shapiro S, Inada M, Krane S, Allen E, Chung D, Weiss SJ: Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1- MMP. J Cell Biol 2004; 167: 769-781.
13. Shimada K, Nakamura M, Ishida E, Higuchi T, Yamamoto H, Tsujikawa K, Konishi N: Prostate cancer antigen-1 contributes to cell survival and invasion though discoidin receptor 1 in human prostate cancer. Cancer Sci 2008; 99: 39-45.
14. Greider CW, Blackburn EH: Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43: 405-413.
15. Greider CW, Blackburn EH: A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989; 337: 331-337.
16. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR, Jefferson RA: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 1997; 6: 2011-2019.
17. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, et al: The RNA component of human telomerase. Science 1995; 269: 1236-1241.
18. Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, Arruda I, Robinson MO: A mammalian telomerase-associated protein. Science 1997; 275: 973-977.
19. Ducrest AL, Szutorisz H, Lingner J, Nabholz M: Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002; 21: 541-552.
20. Juo P, Woo MS, Kuo CJ, Signorelli P, Biemann HP, Hannun YA, Blenis J: FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ 1999; 10: 797-804.
21. Chen G, Bhojani MS, Heaford AC, Chang DC, Laxman B, Thomas DG, Griffin LB, Yu J, Coppola JM, Giordano TJ, Lin L, Adams D, Orringer MB, Ross BD, Beer DG, Rehemtulla A: Phosphorylated FADD induces NF- B, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci USA 2005; 102: 12507-12512.
22. Amit S, Ben-Neriah Y: NF- B activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol 2003; 13: 15-28.
23. Sheikh MS, Huang Y: The FADD is going nuclear. Cell Cycle 2003; 2: 346-347.
24. Kabra NH, Kang C, Hsing LC, Zhang J, Winoto A: T cell-specific FADD-deficient mice: FADD is required for early T cell development. Proc Natl Acad Sci USA 2001; 98: 6307-6312.
25. Gomez-Angelats M, Cidlowski JA: Molecular evidence for the nuclear localization of FADD. Cell Death Differ 2003; 10: 791-797.
26. Screaton RA, Kiessling S, Sansom OJ, Millar CB, Maddison K, Bird A, Clarke AR, Frisch SM: Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: a potential link between genome surveillance and apoptosis. Proc Natl Acad Sci USA 2003; 100: 5211-5216.
27. Shimada K, Nakamura M, Ishida E, Kishi M, Matsuyoshi S, Konishi N: The molecular mechanism of sensitization to Fas-mediated apoptosis by 2-methoxyestradiol in PC3 prostate cancer cells. Mol Carcinog 2004; 39: 1-9.
28. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, RaghaVan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
29. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.